Summary
AbbVie Inc. (ABBV) has announced an extension of its previously initiated exchange offers and consent solicitations related to Allergan's outstanding notes. These offers, which allow holders of Allergan notes to exchange them for new AbbVie notes and consent to amendments that would remove certain covenants and restrictive provisions, were extended from March 27, 2020, to April 10, 2020. This extension is directly tied to AbbVie's ongoing acquisition of Allergan plc, with the settlement date of these offers expected to coincide with the closing of the acquisition. The primary driver for this filing is the procedural adjustment to the debt exchange process, aligning it with the anticipated closing of the Allergan acquisition. Investors should note that the successful completion of the acquisition remains a condition for the settlement of these exchange offers. The extension provides additional time for the acquisition to close, and consequently, for the debt restructuring to be finalized. The underlying purpose is to streamline Allergan's debt structure post-acquisition.
Key Highlights
- 1AbbVie extended the expiration date for its exchange offers and consent solicitations for Allergan notes.
- 2The new expiration date is April 10, 2020, moved from the previous date of March 27, 2020.
- 3These offers are in connection with AbbVie's proposed acquisition of Allergan plc.
- 4The exchange offers allow holders of Allergan notes to exchange them for new AbbVie notes.
- 5The consent solicitations aim to amend Allergan notes by eliminating substantially all covenants, restrictive provisions, and events of default.
- 6Settlement of the exchange offers is conditioned upon the consummation of the Allergan acquisition and is expected to occur promptly after the expiration date, potentially on the closing date.
- 7The AbbVie notes offered have not been registered under the Securities Act and are subject to registration or exemption requirements.